Glucagon-Like Peptide-1 (GLP-1) is an incretin peptide secreted from intestinal L-cells,
whose potent plasma glucose-lowering action has prompted intense efforts to develop GLP-1 …

BACKGROUND. Metformin reduces plasma glucose and has been shown to increase
glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 …

Background Guidelines recommend metformin as the first-line oral treatment for type 2
diabetes. We conducted a systematic review to assess whether the use of second- and third-…

The bile acid receptor TGR5 (also known as GPBAR1) is a promising target for the
development of pharmacological interventions in metabolic diseases, including type 2 diabetes, …

… *Address all correspondence and requests for reprints to: David P. Sonne, MD, PhD,
Center for Diabetes Research, Department of Medicine, Gentofte Hospital, University of …

Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment options
remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-…

Bile acid sequestrants have been used for decades for the treatment of hypercholesterolaemia.
Sequestering of bile acids in the intestinal lumen interrupts enterohepatic recirculation of …

Aim To evaluate the effects of the primary human bile acid, chenodeoxycholic acid ( CDCA ),
and the bile acid sequestrant ( BAS ) colesevelam, instilled into the stomach, on plasma …

Metformin is an oral antihyperglycaemic drug used in the first‐line treatment of type 2 diabetes.
Metformin's classic and most well‐known blood glucose‐lowering mechanisms include …

… Author links open overlay panel Morten Hansen a b 1 , David P. Sonne a , Kristian H. … total
cholesterol in trials with no intervention control group (P < 0.001) versus trials with a placebo …